Abstract 6620: PDX models of TNBC established from pre- and post-therapy tumors identify vulnerabilities of resistant disease
Amanda L. Rinkenbaugh(University of North Carolina at Chapel Hill), Helen Piwnica‐Worms(Centre for Cancer Biology), Chunxiao Fu(The University of Texas MD Anderson Cancer Center), Jason B. White(The University of Texas MD Anderson Cancer Center), Shirong Cai(Sun Yat-sen University), Reid T. Powell(Texas A&M Health Science Center), Sabrina L. Jeter-Jones(The University of Texas MD Anderson Cancer Center), Gloria V. Echeverria(Baylor College of Medicine), Clifford Stephan(Texas A&M Health Science Center), Peter J. Davies(IJ Research (United States)), Lei Guo(Second Military Medical University), Faiza Baameur Hancock(The University of Texas MD Anderson Cancer Center), Xiaomei Zhang(The University of Texas MD Anderson Cancer Center), Yuan Qi(The University of Texas MD Anderson Cancer Center), Stacy Moulder(The University of Texas MD Anderson Cancer Center), Jiansu Shao(The University of Texas MD Anderson Cancer Center), W. Fraser Symmans(The University of Texas MD Anderson Cancer Center), Rebekah Gould(The University of Texas MD Anderson Cancer Center), Jeffrey T. Chang(Tufts University)
Cited by 1
Related Papers
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy
|Journal of Clinical Oncology|2007|1.6k
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features
|Proceedings of the National Academy of Sciences|2009|1.4k
Neoadjuvant Chemotherapy, Endocrine Therapy, and Targeted Therapy for Breast Cancer: ASCO Guideline
|Journal of Clinical Oncology|2021|991